vs
ASSOCIATED BANC-CORP（ASB）与ICU MEDICAL INC（ICUI）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是ASSOCIATED BANC-CORP的1.4倍（$540.7M vs $383.0M），ASSOCIATED BANC-CORP净利率更高（31.2% vs -2.9%，领先34.1%），过去两年ASSOCIATED BANC-CORP的营收复合增速更高（9.1% vs -2.3%）
联合银行集团（Associated Banc-Corp）是美国区域性银行控股公司，总部位于威斯康星州格林贝，深耕美国中西部地区，主营零售银行、商业银行、商业地产贷款、私人银行及特色金融服务，在威斯康星州、伊利诺伊州、明尼苏达州设有220多个营业网点，覆盖100多个社区，还在印第安纳、密歇根等多州设有贷款办事处。
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
ASB vs ICUI — 直观对比
营收规模更大
ICUI
是对方的1.4倍
$383.0M
净利率更高
ASB
高出34.1%
-2.9%
两年增速更快
ASB
近两年复合增速
-2.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $383.0M | $540.7M |
| 净利润 | $119.6M | $-15.7M |
| 毛利率 | — | 37.5% |
| 营业利润率 | — | 1.0% |
| 净利率 | 31.2% | -2.9% |
| 营收同比 | — | -14.1% |
| 净利润同比 | 566.6% | 34.0% |
| 每股收益（稀释后） | $0.70 | $-0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASBICUI
| Q1 26 | $383.0M | — | ||
| Q4 25 | $310.0M | $540.7M | ||
| Q3 25 | $305.2M | $537.0M | ||
| Q2 25 | $300.0M | $548.9M | ||
| Q1 25 | $285.9M | $604.7M | ||
| Q4 24 | $270.3M | $629.8M | ||
| Q3 24 | $329.7M | $589.1M | ||
| Q2 24 | $321.8M | $596.5M |
净利润ASBICUI
| Q1 26 | $119.6M | — | ||
| Q4 25 | $137.1M | $-15.7M | ||
| Q3 25 | $124.7M | $-3.4M | ||
| Q2 25 | $111.2M | $35.3M | ||
| Q1 25 | $101.7M | $-15.5M | ||
| Q4 24 | $-161.6M | $-23.8M | ||
| Q3 24 | $88.0M | $-33.0M | ||
| Q2 24 | $115.6M | $-21.4M |
毛利率ASBICUI
| Q1 26 | — | — | ||
| Q4 25 | — | 37.5% | ||
| Q3 25 | — | 37.4% | ||
| Q2 25 | — | 37.9% | ||
| Q1 25 | — | 34.7% | ||
| Q4 24 | — | 36.1% | ||
| Q3 24 | — | 34.8% | ||
| Q2 24 | — | 34.8% |
营业利润率ASBICUI
| Q1 26 | — | — | ||
| Q4 25 | 52.6% | 1.0% | ||
| Q3 25 | 50.5% | 2.6% | ||
| Q2 25 | 46.5% | 1.9% | ||
| Q1 25 | 42.3% | 2.1% | ||
| Q4 24 | -65.8% | 6.0% | ||
| Q3 24 | 32.8% | 1.4% | ||
| Q2 24 | 32.0% | 1.3% |
净利率ASBICUI
| Q1 26 | 31.2% | — | ||
| Q4 25 | 44.2% | -2.9% | ||
| Q3 25 | 40.9% | -0.6% | ||
| Q2 25 | 37.1% | 6.4% | ||
| Q1 25 | 35.6% | -2.6% | ||
| Q4 24 | -59.8% | -3.8% | ||
| Q3 24 | 26.7% | -5.6% | ||
| Q2 24 | 35.9% | -3.6% |
每股收益（稀释后）ASBICUI
| Q1 26 | $0.70 | — | ||
| Q4 25 | $0.80 | $-0.63 | ||
| Q3 25 | $0.73 | $-0.14 | ||
| Q2 25 | $0.65 | $1.43 | ||
| Q1 25 | $0.59 | $-0.63 | ||
| Q4 24 | $-1.10 | $-0.97 | ||
| Q3 24 | $0.56 | $-1.35 | ||
| Q2 24 | $0.74 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $5.0B | $2.1B |
| 总资产 | $45.6B | $4.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASBICUI
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $308.6M | ||
| Q3 24 | — | $312.5M | ||
| Q2 24 | — | $302.6M |
总债务ASBICUI
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | — | ||
| Q3 25 | $594.1M | — | ||
| Q2 25 | $593.5M | — | ||
| Q1 25 | $591.4M | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $844.3M | — | ||
| Q2 24 | $536.1M | — |
股东权益ASBICUI
| Q1 26 | $5.0B | — | ||
| Q4 25 | $5.0B | $2.1B | ||
| Q3 25 | $4.9B | $2.1B | ||
| Q2 25 | $4.8B | $2.1B | ||
| Q1 25 | $4.7B | $2.0B | ||
| Q4 24 | $4.6B | $2.0B | ||
| Q3 24 | $4.4B | $2.0B | ||
| Q2 24 | $4.2B | $2.0B |
总资产ASBICUI
| Q1 26 | $45.6B | — | ||
| Q4 25 | $45.2B | $4.1B | ||
| Q3 25 | $44.5B | $4.1B | ||
| Q2 25 | $44.0B | $4.1B | ||
| Q1 25 | $43.3B | $4.2B | ||
| Q4 24 | $43.0B | $4.2B | ||
| Q3 24 | $42.2B | $4.3B | ||
| Q2 24 | $41.6B | $4.3B |
负债/权益比ASBICUI
| Q1 26 | — | — | ||
| Q4 25 | 0.20× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.13× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.19× | — | ||
| Q2 24 | 0.13× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $60.6M |
| 自由现金流经营现金流 - 资本支出 | — | $36.0M |
| 自由现金流率自由现金流/营收 | — | 6.6% |
| 资本支出强度资本支出/营收 | — | 4.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $91.8M |
8季度趋势，按日历期对齐
经营现金流ASBICUI
| Q1 26 | — | — | ||
| Q4 25 | $218.1M | $60.6M | ||
| Q3 25 | $158.0M | $56.7M | ||
| Q2 25 | $141.5M | $11.2M | ||
| Q1 25 | $98.2M | $51.3M | ||
| Q4 24 | $207.1M | $40.2M | ||
| Q3 24 | $105.1M | $36.1M | ||
| Q2 24 | $113.5M | $82.0M |
自由现金流ASBICUI
| Q1 26 | — | — | ||
| Q4 25 | — | $36.0M | ||
| Q3 25 | — | $27.6M | ||
| Q2 25 | — | $-8.5M | ||
| Q1 25 | — | $36.7M | ||
| Q4 24 | — | $16.1M | ||
| Q3 24 | — | $16.2M | ||
| Q2 24 | — | $62.5M |
自由现金流率ASBICUI
| Q1 26 | — | — | ||
| Q4 25 | — | 6.6% | ||
| Q3 25 | — | 5.1% | ||
| Q2 25 | — | -1.5% | ||
| Q1 25 | — | 6.1% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 10.5% |
资本支出强度ASBICUI
| Q1 26 | — | — | ||
| Q4 25 | — | 4.6% | ||
| Q3 25 | — | 5.4% | ||
| Q2 25 | — | 3.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | — | 3.4% | ||
| Q2 24 | — | 3.3% |
现金转化率ASBICUI
| Q1 26 | — | — | ||
| Q4 25 | 1.59× | — | ||
| Q3 25 | 1.27× | — | ||
| Q2 25 | 1.27× | 0.32× | ||
| Q1 25 | 0.97× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.19× | — | ||
| Q2 24 | 0.98× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASB
| Net Interest Income | $307.2M | 80% |
| Noninterest Income | $75.9M | 20% |
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
